Palvella Therapeutics, Inc.
PVLA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001583648
In the last 90 days, Palvella Therapeutics, Inc. insiders filed 0 open-market purchases and 5 sales; 196 institutions reported holding it in 13F filings for Q2 2026, worth $2.15B in total; no superinvestor holds it.
Q3 2025 vs. Q2 2025
How the institutions holding Palvella Therapeutics, Inc. changed between Q2 2025 and Q3 2025.
All holders in Q3 2025All holders in Q2 2025
| Measure | Q2 2025 | Q3 2025 | Change |
|---|---|---|---|
| Holders | 67 | 100 | +33 |
| Shares | 5.91M | 8.53M | +2.62M (+44.3%) |
| Value | $133.2M | $534.5M | +$401.3M (+301.2%) |
New holders (42)
Institutions that held Palvella Therapeutics, Inc. at the end of Q3 2025 but not at the end of Q2 2025.
Sold out (9)
Institutions that held Palvella Therapeutics, Inc. at the end of Q2 2025 and filed for Q3 2025 without it.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| Adams Street Partners LLC | 298,986 | $6.74M |
| Marshall Wace, LLP | 49,077 | $1.11M |
| UBS Oconnor LLC | 43,994 | $991.6K |
| DAFNA Capital Management LLC | 43,348 | $977.1K |
| Strid Group, LLC | 18,166 | $409.5K |
| XTX Topco Ltd | 17,701 | $399.0K |
| SBI Securities Co., Ltd. | 12 | $270 |
| Twin Peaks Wealth Advisors, LLC | 1 | $43 |
| Acadian Asset Management LLC | 1 | $0 |